More and more studies reveal that fasting is not simply a pause in eating, but a powerful biological trigger that activates mechanisms of repair, defense, and cellular cleansing. Far from weakening the body, certain types of fasting appear to strengthen it—particularly in its ability to detect and eliminate abnormal cells, including tumor cells. In this context, fasting emerges not as an isolated strategy but as a potential complementary tool within the therapeutic arsenal against cancer. How is it possible that something as ancient and natural as not eating could reprogram metabolism, refine immune response, and make cancer treatment more effective? Science is beginning to provide answers.
In recent years, fasting has evolved from being considered a spiritual or alternative practice to becoming a legitimate subject of biomedical research. The scientific community is beginning to understand that the human body is not only designed to survive periods of scarcity, but that under such conditions, it activates molecular adaptation programs that promote energy efficiency, elimination of damaged cells, and tissue regeneration. Far from being a state of weakness, well-managed fasting is a phase of profound cellular reorganization. This metabolic reprogramming not only reduces factors that promote tumor growth—such as hyperglycemia or hyperinsulinemia—but also modifies the systemic environment in which both the tumor and the immune system operate.
The Warburg effect, widely documented in oncology, describes how many cancer cells prefer rapid glycolysis over mitochondrial respiration—even when oxygen is available. This strategy, though inefficient in the long term, allows them to grow and divide quickly. But it also makes them dependent on a constant supply of glucose and amino acids. Fasting breaks this supply chain, forcing cells to compete in a state of scarcity. Normal cells, more plastic and evolutionarily prepared for such conditions, switch to alternative pathways like fatty acid oxidation and ketone body utilization. Cancer cells, on the other hand, enter crisis: they accumulate reactive oxygen species, suffer endoplasmic reticulum stress and mitochondrial failure, and in some cases, activate programmed cell death pathways like apoptosis or necroptosis.
Moreover, modulation of the immune system is one of the most fascinating effects of fasting. Far from suppressing defenses, intermittent or simulated fasting appears to enhance immune surveillance. Studies in animals and humans have observed increased natural killer cell activity, greater efficiency in antigen presentation by dendritic cells, and expansion of long-lived memory T lymphocytes. At the same time, the overproduction of inflammatory cytokines that can interfere with a precise immune response is reduced. Put simply, fasting silences metabolic noise and allows the immune system to better detect the real signal of danger: the tumor.
The clinical use of Fasting Mimicking Diets (FMDs) has become a particularly interesting tool for cancer patients. This approach allows for the induction of deep fasting effects without completely depriving the patient of nutrients. In various clinical trials, applying short FMD cycles before initiating treatments such as chemotherapy improved tolerance and efficacy by creating a metabolic environment that is unfavorable to malignant cells while protecting healthy tissue. This differential protection—the fact that normal cells better resist treatment-induced stress under fasting, while cancer cells become more sensitive—is one of the most promising physiological principles behind this strategy.
Another emerging field is the targeted restriction of specific nutrients like asparagine or methionine. Instead of reducing all calories, some researchers focus on eliminating specific dietary components that tumors need to grow. Asparagine, for example, has been linked to metastatic spread in breast cancer. Reducing its availability—through diet or drugs like asparaginase—could limit the invasive capacity of tumors while also enhancing immune memory. In the future, it’s not far-fetched to imagine personalized nutritional plans in which the metabolic vulnerabilities of each type of cancer are identified and diets are adjusted to therapeutically exploit them.
In addition to the metabolic and immunological effects, fasting may also influence the tumor microenvironment itself—a dynamic and often immunosuppressive niche that protects cancer cells from attack. Emerging evidence suggests that fasting can alter this local environment by reducing angiogenesis (the formation of new blood vessels that feed tumors), decreasing extracellular matrix stiffness, and even modulating the population of stromal cells that support tumor growth. By softening the biochemical and mechanical defenses of the tumor, fasting may facilitate the infiltration of immune cells and increase the efficacy of immune checkpoint inhibitors and adoptive cell therapies.
Another intriguing avenue lies in the connection between fasting and circadian biology. The body’s internal clock regulates a host of physiological processes, including metabolism, hormone secretion, immune activity, and cell cycle progression. Disruption of circadian rhythms—common in modern lifestyles and in many cancer patients—has been associated with poor immune surveillance and increased tumor risk. Fasting, particularly time-restricted eating (e.g., 16:8 or 18:6 protocols), may help realign circadian rhythms and restore a more synchronized hormonal and immunological state, potentially enhancing therapeutic outcomes. Some researchers even suggest that aligning treatment schedules with periods of fasting and circadian peaks—an approach known as chrono-nutrition or chrono-oncology—could optimize both drug delivery and immune readiness.
Beyond physiology, fasting introduces a powerful psychological and existential component into cancer care. For many patients, reclaiming agency over their health through nutritional strategies offers a sense of empowerment in an otherwise overwhelming medical journey. Fasting can represent a conscious pause—a ritualized, intentional process of preparation, reflection, and reorganization. While such aspects are less quantifiable in clinical trials, they should not be underestimated. Emotional resilience, psychological coherence, and lifestyle integration are all critical to long-term survivorship and treatment adherence.
Figure 1. It reduces glucose and inflammation, enhances immune cell activity, and increases the effectiveness of immunotherapy.
Of course, the implementation of fasting in cancer care must be individualized, scientifically grounded, and culturally sensitive. What works for one patient may be contraindicated for another. Factors such as tumor type, stage, nutritional status, comorbidities, ongoing treatments, and patient preferences must all be taken into account. Fasting is not a magic bullet, nor a substitute for evidence-based therapies—but when integrated thoughtfully and ethically, it may amplify the body’s natural wisdom and biological resilience.
In the future, we may envision integrative oncology programs that combine fasting protocols with tumor profiling, microbiome modulation, circadian rhythm support, personalized nutrition, and immunotherapeutic scheduling. Such approaches would not merely target the tumor as an isolated entity but would support the entire host system in its capacity to adapt, defend, and regenerate. Cancer, after all, is not only a disease of uncontrolled growth, but also of disrupted balance—between cells, signals, and systems. Fasting, in its simplicity and depth, may help restore that balance.
Main Reference:
Vernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., Lalli, L., Chiodoni, C., Cancila, V., Zanardi, F., Ajazi, A., Cortellino, S., Vallacchi, V., Squarcina, P., Cova, A., Pesce, S., … de Braud, F. (2022). Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer discovery, 12(1), 90–107. https://doi.org/10.1158/2159-8290.CD-21-0030
Other References:
Chang, H. C., Tsai, C. Y., Hsu, C. L., Tai, T. S., Cheng, M. L., Chuang, Y. M., Tang, H. Y., Lin, K. J., Chen, J. J., Chang, S. H., Ko, Y. C., Chi, Y. W., Liu, H., Tan, B. C., Shen, C. R., Yang, C. W., Ho, P. C., & Yang, H. Y. (2025). Asparagine deprivation enhances T cell antitumour response in patients via ROS-mediated metabolic and signal adaptations. Nature metabolism, 7(5), 918–927. https://doi.org/10.1038/s42255-025-01245-6
Lee, C., Raffaghello, L., Brandhorst, S., Safdie, F. M., Bianchi, G., Martin-Montalvo, A., Pistoia, V., Wei, M., Hwang, S., Merlino, A., Emionite, L., de Cabo, R., & Longo, V. D. (2012). Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Science translational medicine, 4(124), 124ra27. https://doi.org/10.1126/scitranslmed.3003293 {
Lee, C., Safdie, F. M., Raffaghello, L., Wei, M., Madia, F., Parrella, E., Hwang, D., Cohen, P., Bianchi, G., & Longo, V. D. (2010). Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer research, 70(4), 1564–1572. https://doi.org/10.1158/0008-5472.CAN-09-3228
